Therapy

Delivering Where it Matters Most 
TransCode Therapeutics is initially focusing on the area of oncology with the largest unmet need -- metastatic cancers. Given the absence of treatments targeting metastatic disease, TransCode is applying their TTX platform in the metastatic setting first to transform the lives of people with metastatic disease and improve outcomes.
 
We are immediately focused on the urgent need for metastatic breast cancer treatment and are extending our TTX platform and therapy there. 
 
Rooted in our fundamental principle to change how all cancer is treated and in our commitment to patients, TransCode aims to extend TTX across tumor types and across all stages of cancer.

Technology

Committed to Unlocking the Power and Potential of RNA-based Therapies

TransCode Therapeutics is dedicated to bringing the power of RNA therapeutics to oncology. 

By applying our TTX platform, TransCode is able to boldly do what no other company has done before:

• Access targets previously deemed undruggable for small molecules and other protein-based therapies
• Address and overcome challenges in immune escape and tumor resistance
• Directly interfere with the pathways known to be involved in tumorigenesis and metastasis

​TTX opens the door for us to harness RNA’s ability to target a vast number of genes and cellular pathways with high specificity. The rapid and cost-effective development of these therapies also allows for the easy modification to address personalized medicine and evolving targets. 

We won’t stop in our mission to leverage TTX to find new targets and treatments.
​
TransCode is committed to revolutionizing the future of cancer treatment through application of the TTX platform to deliver on the promise of RNA in oncology.

Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16(4):201-218. Liang X, et al. Biomed Pharmacother. 2020;125:109997.;
​Damase TR, et al. Frontiers in Bioengineering and Biotechnology. 2021;9.; Dowdy SF. Nat Biotechnol. 2017;35(3):222-229.